JG
BCRX icon

Jefferies Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jefferies Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200,000
Closed -$2.12M – 1653
2022
Q2 		$2.12M Buy
+200,000
New +$2.06M 0.02% 599
2017
Q1 		– Sell
-45,800
Closed -$290K – 2318
2016
Q4 		$290K Buy
45,800
+6,500
+17% +$33.8K ﹤0.01% 1782
2016
Q3 		$173K Buy
+39,300
New +$157K ﹤0.01% 1972

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Jefferies Group's BCRX Position: Q3 2022 in Review

Jefferies Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 76,100 shares — an estimated $805K sold.

Jefferies Group first reported a position in BCRX in Q3 2016 and held it in 5 quarters. The position peaked at $1.09M in Q4 2019. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Jefferies Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 76,100 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $805K.
  • Jefferies Group first reported a position in BioCryst Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • Jefferies Group's BioCryst Pharmaceuticals position peaked at $1.09M in Q4 2019.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.